Mindray initiates voluntary recall for A3/A5 Anesthesia Delivery System

Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, has initiated a voluntary recall affecting the A3/A5 Anesthesia Delivery System.  Mindray has initiated this recall due to the possibility of a system leak resulting from improper seating of the CO2 absorbent canister gasket.

Should a system leak occur during use, fresh gas flow may be increased to compensate for any pressure loss resulting from the leak while the absorbent canister is unlocked and locked again to reseat the gasket. If the CO2 absorbent canister gasket is improperly seated, however, a potential leak will likely present itself during the Automatic Circuit Leak and Compliance Test performed at startup and the Manual Leak Test recommended to be performed before each case, at which time the absorbent canister can be unlocked and locked again to reseat the gasket.

The canister gasket subject to this recall may be identified by presence of a small "step" in the gasket surface.  A3/A5 units with this gasket may continue to be used.  The proper seating of the canister gasket should be confirmed prior to use and after CO2 absorbent is changed.

Customers who have a system(s) subject to this recall were notified by on August 8, 2012 by letter via US Postal Mail, return receipt required. To date, approximately 70% of units affected by this action have been corrected.  The issue is corrected through a replacement of the canister gasket by a Mindray Service or authorized representative.

Units with the affected canister gaskets were shipped between May 31, 2011 and July 15, 2012 in the United States, Latin America and Australia.

There have been no reports of injuries associated with this issue. Mindray became aware of the issue when a system leak was reported by a customer.  The cause of the leak was determined to be the result of an improperly seated canister gasket.

Mindray has advised the US Food and Drug Administration of this voluntary recall.

Any adverse reactions or quality problems experienced with the use of this product may be reported to the U.S. Food and Drug Administration's (FDA) MedWatch Adverse Events Program either online, by regular mail or by fax.

Source:

Mindray Medical International Limited

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mindray. (2019, June 19). Mindray initiates voluntary recall for A3/A5 Anesthesia Delivery System. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20121114/Mindray-initiates-voluntary-recall-for-A3A5-Anesthesia-Delivery-System.aspx.

  • MLA

    Mindray. "Mindray initiates voluntary recall for A3/A5 Anesthesia Delivery System". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20121114/Mindray-initiates-voluntary-recall-for-A3A5-Anesthesia-Delivery-System.aspx>.

  • Chicago

    Mindray. "Mindray initiates voluntary recall for A3/A5 Anesthesia Delivery System". News-Medical. https://www.news-medical.net/news/20121114/Mindray-initiates-voluntary-recall-for-A3A5-Anesthesia-Delivery-System.aspx. (accessed November 22, 2024).

  • Harvard

    Mindray. 2019. Mindray initiates voluntary recall for A3/A5 Anesthesia Delivery System. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20121114/Mindray-initiates-voluntary-recall-for-A3A5-Anesthesia-Delivery-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mindray announces definitive agreement to acquire remaining stake in Dragonbio for US$72.6 million